Taken together, these data suggest that ESR1 mutations in the LBD maintain the ERα-driven transcriptional program within these cancer cells, even in the absence of estrogenic ligand; thus contributing to endocrine resistance [30]. The gene discussed is ESR1; the disease is cancer.